{"entity":{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","aka":[],"tldr":"Primo Lara is a GU and lung oncologist who co-chairs SWOG and directs UC Davis's cancer centre.","summary":"Primo Lara Jr. is Group Co-Chair of the SWOG Cancer Research Network and Director of the UC Davis Comprehensive Cancer Center. A genitourinary and lung medical oncologist, his research spans bladder, kidney and prostate cancer trials and phase 1 drug development, and he co-chairs SWOG with Dawn Hershman. His papers include a Journal of Clinical Oncology randomised phase III trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan in advanced non-small-cell lung cancer and a Lancet randomised phase 2 comparison of sunitinib with cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma. His work covers bladder and urothelial cancer, renal cell carcinoma, prostate cancer and non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lara%20PN%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Primo%20N.%20Lara%20Jr."}],"tags":[],"related":[],"cancers":["urothelial","rcc","prostate","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":["uc-davis-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Co-Chair, SWOG Cancer Research Network; Director, UC Davis Comprehensive Cancer Center","institutionId":"swog","specialisms":["Genitourinary oncology","Lung cancer","Clinical trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lara%20PN%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Primo%20N.%20Lara%20Jr."}],"papers":[{"title":"Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer","journal":"Journal of Clinical Oncology","year":2011,"url":"https://doi.org/10.1200/jco.2011.35.0660","doi":"10.1200/jco.2011.35.0660"},{"title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)00152-5","doi":"10.1016/S0140-6736(21)00152-5"}]},"route":"/people/primo-lara/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"institution":[{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/"}]}}